Ann Hematol:胸腺MALT淋巴瘤的分子遗传学和临床病理特征

2021-10-08 MedSci原创 MedSci原创

导致NF-κB通路激活的分子畸变参与了胸腺MALT淋巴瘤的发病机制,涉及NF-κ b通路的分子畸变在胸腺MALT淋巴瘤中很常见,CCND3突变提示PI3K通路失调可能也参与了胸腺MALT淋巴瘤的发病机

粘膜相关淋巴样组织的结外边缘区b细胞淋巴瘤 (MALT) 是一种低度恶性b细胞淋巴瘤。胸腺MALT淋巴瘤的临床病理特征由于该疾病的罕见性仍然较差。到目前为止,还没有研究探索胸腺MALT淋巴瘤的分子特征。目前尚不清楚胸腺MALT淋巴瘤是否具有类似于其他解剖部位的MALT淋巴瘤的突变景观。

国外一研究团队调查了来自单一中心的11例胸腺MALT淋巴瘤的临床病理特征。此外,对有可用样本的患者进行了靶向基因测序。这项研究的目的是研究胸腺MALT淋巴瘤的临床病理特征。还对相关文献进行了回顾。

11例患者的中位年龄为50岁 (range33-60)。女性占主导地位,男女比例为101。3例患者分别出现干燥综合征,自身免疫性血小板减少性紫癜和B1型胸腺瘤。显微镜下,胸腺MALT淋巴瘤的特征是上皮衬里的囊肿,周围是小淋巴细胞,中心细胞样细胞和单核细胞样b细胞。在两例病例中观察到浆细胞分化。肿瘤细胞表达CD20,CD79α 和bcl2。在所有8例检查病例中均检测到克隆免疫球蛋白基因。7例进行了18q21的荧光原位杂交 (FISH),未发现涉及18q21的易位。在5例有可用DNA样本的病例中进行了靶向基因测序,并鉴定出TNFAIP3,CARD11,IGLL5和CCND3突变。

研究表明,导致NF-κB通路激活的分子畸变参与了胸腺MALT淋巴瘤的发病机制,涉及NF-κ b通路的分子畸变在胸腺MALT淋巴瘤中很常见,CCND3突变提示PI3K通路失调可能也参与了胸腺MALT淋巴瘤的发病机制。由于使用的是靶向基因测序,没有检测到不包含在当前面板中的基因发生的突变。由于涉及其他基因的突变也可能有助于胸腺MALT淋巴瘤的发展,需要全外显子组测序,以更好地防御胸腺MALT淋巴瘤的遗传景观。未来使用RNA测序或全基因组测序来检测致病性染色体易位也很重要。

 

原始出处:

Wang, X., Miao, Y., Cao, Z. et al. Characterization of molecular genetics and clinicopathology in thymic MALT lymphoma. Ann Hematol (2021). https://doi.org/10.1007/s00277-021-04671-0

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2022-06-25 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-10 柳叶一刀

相关资讯

Ⅲ期胃癌患者应尽可能施行R0根治术

  近日,中国医科大学附属第一医院胃肠肿瘤外科徐岩、孙哲、王振宁等人发表论文,旨在探讨Ⅲ期胃癌(按第7版TNM分期标准)的临床病理特征及影响预后的相关因素。研究指出,Ⅲ期胃癌患者有其自身的临床病理学特点,治疗上应尽可能施行R0根治术。淋巴结转移数目、肿瘤浸润深度和Borrmann分型是影响接受R0手术的Ⅲ期胃癌患者预后的重要因素。该文发表在2012年第15卷第2期《中华胃肠外科杂志》上。   回

SCI REP:胃腺鳞癌的临床病理特征及预后!

由此可见,胃部ASC与AC在临床病理特征上具有明显的不同,并且胃部ASC的预后要明显差于AC。

拓展阅读

European Radiology:使用[18F]FDG PET/CT实现结节病和淋巴瘤的准确诊断

[18F]FDG PET/CT是一种诊断成像技术,可用于评估癌症和炎症性疾病的活动。卷积神经网络 (CNN) 是一种深度学习编码,由多个卷积和池化层组成,可以从输入图像中自动提取特征图。

2年无进展生存率超70%!《柳叶刀》子刊:CD30 CAR-T,淋巴瘤治疗新希望

近日,《柳叶刀-血液学》发表一项1期临床研究结果,表明靶向CD30的CAR-T细胞疗法(ATLCAR.CD30)有潜力作为高风险霍奇金淋巴瘤患者在自体HSCT后的巩固治疗。

【Blood Adv】通过免疫表型监测CAR-T扩增,揭示不同淋巴瘤的扩增与毒性

为了解CD19 CAR-T扩增对输注后1个月内患者结局的影响,斯坦福大学专家前瞻性研究了单中心接受CD19 CAR-T治疗的236例患者。研究结果近日发表于《Blood Advances》。

European Radiology:MRI弥散加权成像和[18F]FDG PET/MRI在小儿霍奇金淋巴瘤和非霍奇金淋巴瘤治疗监测中的比较

现阶段,PET/MRI是FDG PET/CT的可靠替代方法。然而,FDG PET/MRI仅限于世界领先国家的大型三级医疗中心,而传统MRI在全球范围内都可以使用。

淋巴瘤国际预后指数(IPI)

淋巴瘤国际预后指数(IPI)

European Radiology:[18F]FDG PET/MRI在儿童淋巴瘤中的应用

目前FDG PET/磁共振成像(MRI) 已成为所有淋巴瘤患者 (尤其是儿童)的初始分期和随访成像的一种重要的替代方法,可以减少高达65%的辐射暴露,同时可在淋巴瘤成像中获得高质量图像。

中国淋巴瘤治疗指南(2023年版)

暂未更新 · 2023-04-28

彼得·麦卡勒姆癌症中心发表的澳大利亚临床实践声明:CD30阳性淋巴细胞增殖性疾病

彼得·麦卡勒姆癌症中心the Peter MacCallum Cancer Centre · 2023-03-09

2022 国际共识:急性淋巴细胞白血病/淋巴瘤的分类

国外血液科相关专家小组 · 2022-11-24

淋巴瘤诊疗指南 (2022年版)

国家癌症中心 · 2022-04-11

中国蒽环类药物治疗淋巴瘤专家共识

中国抗癌协会肿瘤临床化疗专业委员会 · 2021-11-20